Approximately 8% of the DNA in the human body is derived from the remnants of retroviruses that infected ancient human ancestors. These retroviruses reverse-transcribed their own RNA into DNA, which integrated into the human genetic material and has been inherited by humans to the present day.

Lupus erythematosus is a chronic and relapsing autoimmune disease, commonly affecting women aged 20–40 years. Based on the site of pathological involvement, it is classified into cutaneous lupus erythematosus (CLE), which is confined to the skin, and systemic lupus erythematosus (SLE), which affects multiple organs throughout the body.

Owing to its multiple advantages, nanobodies have been widely applied and studied in the field of biological research. Beyond the mainstream research directions, they also hold great potential in the fields of food safety and agricultural development. Nowadays, this technology is gradually being applied to research in the field of transdermal drug delivery.

Recently, Ivonescimab Injection, independently developed by Akeso-Sino Biopharmaceutical Co., Ltd. and the world's first of its kind, has been officially approved for marketing. Combined with chemotherapy, Ivonescimab Injection is expected to provide a brand-new and highly effective immunotherapeutic regimen for patients with locally advanced or metastatic non-squamous non-small cell lung cancer.